- Home
- XAIR vs CLRB Comparison
XAIR vs CLRB Comparison
Compare XAIR & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XAIR
- CLRB
- Stock Information
- Founded
- XAIR 2011
- CLRB 2002
- Country
- XAIR United States
- CLRB United States
- Employees
- XAIR N/A
- CLRB N/A
- Industry
- XAIR Medical/Dental Instruments
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- XAIR Health Care
- CLRB Health Care
- Exchange
- XAIR Nasdaq
- CLRB Nasdaq
- Market Cap
- XAIR 17.0M
- CLRB 14.2M
- IPO Year
- XAIR N/A
- CLRB N/A
- Fundamental
- Price
- XAIR $2.40
- CLRB $5.15
- Analyst Decision
- XAIR Strong Buy
- CLRB Hold
- Analyst Count
- XAIR 1
- CLRB 2
- Target Price
- XAIR $11.00
- CLRB N/A
- AVG Volume (30 Days)
- XAIR 8.8M
- CLRB 129.4K
- Earning Date
- XAIR 11-10-2025
- CLRB 08-14-2025
- Dividend Yield
- XAIR N/A
- CLRB N/A
- EPS Growth
- XAIR N/A
- CLRB N/A
- EPS
- XAIR N/A
- CLRB N/A
- Revenue
- XAIR $4,782,000.00
- CLRB N/A
- Revenue This Year
- XAIR $265.24
- CLRB N/A
- Revenue Next Year
- XAIR $136.17
- CLRB N/A
- P/E Ratio
- XAIR N/A
- CLRB N/A
- Revenue Growth
- XAIR 168.20
- CLRB N/A
- 52 Week Low
- XAIR $2.02
- CLRB $4.11
- 52 Week High
- XAIR $13.52
- CLRB $67.50
- Technical
- Relative Strength Index (RSI)
- XAIR 48.22
- CLRB 53.59
- Support Level
- XAIR $2.13
- CLRB $4.82
- Resistance Level
- XAIR $4.78
- CLRB $5.34
- Average True Range (ATR)
- XAIR 0.33
- CLRB 0.36
- MACD
- XAIR 0.05
- CLRB 0.07
- Stochastic Oscillator
- XAIR 11.63
- CLRB 79.12
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.